Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma

Johnson, C.D., Puntis, M., Davidson, N., Todd, S. and Bryce, R. (2001) Randomized, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. The British Journal of Surgery, 88, (5), 662-668. (doi:10.1046/j.0007-1323.2001.01770.x).


[img] PDF - Version of Record
Restricted to System admin

Download (1213b)


Background: chemotherapy for pancreatic cancer offers small survival benefits and considerable side-effects. Unsaturated fatty acids have an antitumour effect in experimental studies; in phase II studies few side-effects were seen.

Methods: in this group-sequential, open-label, randomized study, 278 patients with a diagnosis of inoperable pancreatic cancer were treated with either oral (700 mg daily for 15 days), low-dose (0,28 g/kg) or high-dose (0,84 g/kg) intravenous lithium gamolenate (LiGLA). The primary endpoint was survival time from randomization using Kaplan-Meier estimates.

Results: median survival after oral and low-dose intravenous treatment was 129 and 121 days respectively. Median survival after high-dose intravenous treatment was 94 days. A good Karnofsky score and the absence of metastases were associated with increased survival. Haemolysis, a marker of rapid infusion, was associated with a median survival time of 249 days in the low-dose intravenous group.

Conclusion: oral or low-dose intravenous LiGLA led to survival times similar to those of other treatments for pancreatic cancer although one subgroup (low-dose intravenous LiGLA with haemolysis) had longer survival. High-dose intravenous treatment appeared to have an adverse effect. Systemic treatment with LiGLA cannot be recommended for the treatment of pancreatic cancer.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1046/j.0007-1323.2001.01770.x
ISSNs: 0007-1323 (print)
Related URLs:
Subjects: R Medicine > RD Surgery
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: University Structure - Pre August 2011 > School of Medicine > Cancer Sciences
ePrint ID: 26400
Date :
Date Event
1 May 2001Published
Date Deposited: 24 Apr 2006
Last Modified: 31 Mar 2016 11:49
URI: http://eprints.soton.ac.uk/id/eprint/26400

Actions (login required)

View Item View Item

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics